November 22, 2024

VectorBuilder Wins BioIndustrial Innovation of the Year Award

VectorBuilder Wins BioIndustrial Innovation of the Year Award

Chicago, IL – NOVEMBER 19, 2024 – VectorBuilder, a global leader in gene delivery solutions, is excited to announce that it’s received the BioIndustrial Innovation of the Year award by the BioTech Breakthrough Awards. The recognition underscores VectorBuilder’s significant contributions to gene delivery technology through its Vector Design Studio, which has revolutionized the way researchers worldwide create and order custom gene delivery vectors.

Now in its fourth year, the annual BioTech Breakthrough Awards recognize the world’s best life sciences and biotechnology companies, products, and services. VectorBuilder’s platform was selected for its efficiency, user-friendliness, and ability to accelerate research timelines. The Vector Design Studio has become an indispensable tool for over 300,000 life sciences labs globally, meeting the demand for a faster, more reliable vector design and construction solution.

“Winning this reward reflects our continued commitment to accelerating the pace of gene therapy research through advanced technologies and custom-built solutions transforming how diseases are treated,” said Bruce Lahn, Chief Scientist at VectorBuilder. “Our platform’s ability to reduce vector creation timelines from months to just a few weeks allows researchers to focus on what truly matters: advancing knowledge and developing innovative research and therapies.”

Traditionally, labs have relied on in-house cloning for vector creation, a process that can be slow, costly, and inconsistent. VectorBuilder’s Vector Design Studio changes this by offering an intuitive, Web-based platform that allows even novice researchers to design and order custom vectors with just a few clicks. The platform includes access to an extensive library of over 1,100 vector backbones and more than 400,000 vector components, providing tailored vector solutions with unmatched speed and precision.

The platform has achieved widespread success and adoption. To this end, it’s been used to design over one million vectors that have been cited in more than 5,000 publications, including journals like ‘Science,’ ‘Nature,’ and ‘Cell.’

“The Vector Design Studio merges cutting-edge information technology with synthetic and molecular biology to provide a scalable solution for labs of all sizes,” said Lahn. “By automating the process from demand analysis to vector optimization and delivery, we offer a cost-effective model that helps labs accelerate their research timelines and lower labor expenses. This award inspires us to continue pushing the boundaries of what’s possible in gene delivery.”

Beyond its technical innovation, VectorBuilder’s platform also delivers a significant financial impact. With more than 80% of custom vectors made from ready-made elements, VectorBuilder’s streamlined approach allows for large-scale production, enabling labs to complete projects faster and more affordably. The Vector Design Studio has pioneered a new era of large-scale gene vector production, which has the potential to accelerate life sciences research by up to 20%, according to leading investment firm Legend Capital.

VectorBuilder is a global CRO (Contract Research Organization) and CDMO (Contract Development and Manufacturing Organization) providing comprehensive, end-to-end gene delivery solutions, including custom vector design, plasmid production, and viral vector manufacturing. With a strong foundation in GMP manufacturing, VectorBuilder has earned the trust of over 4,500 academic institutions and biotech/pharmaceutical companies worldwide.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Design Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities and state-of-the-art GMP facilities. With leading R&D and CDMO manufacturing capacity, the VectorBuilder team strives to provide the most effective gene delivery solutions and develop new tools for life sciences research and genetic medicine.

Our latest News

discover more
RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

RHEACELL receives EMA approval for allo-APZ2-CVU Phase 3 trial in chronic venous ulcers

Heidelberg, Germany, 19.12.2024 – RHEACELL today received approval from the European Medicines Agency (EMA) for its blinded, multi-centric Phase-3 trial (NCT06489028) evaluating allo-APZ2-CVU in patients with chronic venous ulcers (CVU). The pivotal trial will be conducted at more than 100 sites and is expected to enroll 250 patients, starting enrollment in Europe in Q1 2025. […]

Common cough syrup ingredient shows promise in treating serious lung disease

Common cough syrup ingredient shows promise in treating serious lung disease

EMBL scientists discover that an FDA-approved, over-the-counter cough syrup ingredient has potential to treat fibrotic lung disease. Summary A common over-the-counter ingredient in many cough syrups may have a greater purpose for people suffering from lung fibrosis that is related to any number of serious health conditions.  Scientists from EMBL Heidelberg were part of a […]

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibody that Neutralizes Inhibitory Factors Involved in Nerve Regeneration Leads to Enhanced Motor Function after Acute Spinal Cord Injury

Antibodies can improve the rehabilitation of people with acute spinal cord injury. Researchers at 13 clinics in Germany, Switzerland, the Czech Republic and Spain have investigated this with promising results. For the first time, it was possible to identify patient groups that displayed a clinically relevant treatment effect. A follow-up study will start in December […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp